📰 Development Rd Expense News
Development Rd Expense News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Development Rd Expense. Real-time updates on events, politics, business and more.
June 6, 2024
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force,...
May 16, 2024
Exicure, Inc. , has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force,...
August 12, 2023
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical ac...
August 8, 2023
EstablishedExclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared
July 15, 2023
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical ac...
July 14, 2023
Exicure, Inc. , has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the...
July 14, 2023
14.07.2023 - Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant ...
March 27, 2023
CHICAGO--(BUSINESS WIRE)--Mar 27, 2023--
November 14, 2022
CHICAGO--(BUSINESS WIRE)--Nov 14, 2022--
August 15, 2022
CHICAGO--(BUSINESS WIRE)--Aug 15, 2022--